Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)
||EDTA Buffer pH8.0
||30 min at Room Temperature
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-GATA3 Antibody Clone: L50-823
Host and Isotype: Mouse IgG1
Recommended Positive Control Sample: Breast Carcinoma, Urothelial Carcinomas
Cellular Localization of Antibody L50-823 Staining: Nuclear
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Lot specific. Plese contact tech support
Immunogen: Peptide between trans-activation and DNA-binding domains of GATA-3
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
GATA3 Information for Pathologists
One of 6 members of the GATA family of transcription factors. Involved in the luminal differentiation of breast epithelium, development of collecting system / urothelium and trophoblastic differentiation. Also master regulator of type 2 helper T cells. Essential features Nuclear marker with expression in many epithelial neoplasms (including most breast, urothelial, paraganglioma / pheochromocytoma and skin carcinoma; smaller percentages of lung, liver, pancreatic, gastric, renal, thyroid, endometrial, ovarian and salivary gland carcinoma).
Notable Clinical Features:
GATA3 mutations cause HDR (hypoparathyroidism, sensorineural deafness and renal dysplasia) syndrome (Ann N Y Acad Sci 2011;1237:24, Endocr J 2011;58:117). Uses by pathologists Differentiate metastatic urothelial and breast carcinomas (GATA3+) from many other metastatic carcinomas (Am J Surg Pathol 2014;38:13). Differentiate urothelial carcinoma (> 80% GATA3+) from prostatic carcinoma (2% GATA3+). Differentiate metastatic lobular carcinoma of the breast (GATA3+) from gastric signet ring cell carcinoma (GATA3-).
Common Uses By Pathologists:
Differentiate metastatic urothelial and breast carcinomas (GATA3+) from many other metastatic carcinomas (Am J Surg Pathol 2014;38:13). Differentiate urothelial carcinoma (> 80% GATA3+) from prostatic carcinoma (2% GATA3+). Differentiate metastatic lobular carcinoma of the breast (GATA3+) from gastric signet ring cell carcinoma (GATA3-). Differentiate squamous cell carcinoma of the skin (GATA3+) from squamous cell carcinoma of the lung (GATA3-). Differentiate mesothelioma (81% GATA3+) from pulmonary adenocarcinoma (12% GATA3+).
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.